Distribution or Net Royalties. The Net Royalties as defined above shall be divided between the Inventor(s) (as defined under the patent law) and the University as follows: · The first $100,000 of Net Royalties 50% to the Inventor(s) 50% allocated to the general support of University research, as described in paragraph 5. · Net Royalties between $100,000 and $200,000 40% to the Inventor(s) 60% allocated to the general support of University research, as described in paragraph 5. · Net Royalties exceeding $200,000 30% to the Inventor(s) 70% allocated to the general support of University research, as described in paragraph 5. For purposes of applying the above Net Royalty distribution formula (i.e., whether aggregate Net Royalties are $100,000 or less, between $100,000 and $200,000, or more than $200,000), equity shall be deemed to have the per-share value agreed upon in a good-faith negotiation between the University and the licensee at the time the license agreement is executed, and the equity shall be deemed received after all cash Net Royalties received at or before the time the equity is issued. In the absence of such negotiated value, the Inventors shall receive 32% of the equity Net Royalties. In its discretion, the University may either distribute equity to the Inventor(s) when it is received or arrange for the licensee to issue the Inventor’s share of equity directly to the Inventor(s). As used in this document, the term “Inventor” may represent two or more individuals. These individuals will be expected to agree among themselves on the fractional distribution of the “Inventor” share of any royalties. A written agreement must be signed by all the individuals involved, and deposited for the record in the Office of Cooperative Research. (Appropriate forms are available from the Office of Cooperative Research.) If no written agreement has been deposited at the time of a distribution of Net Royalties, the Inventors’ share of such distribution shall be divided equally among the Inventors.
Appears in 4 contracts
Samples: License Agreement, License Agreement (Celldex Therapeutics, Inc.), License Agreement (Kolltan Pharmaceuticals Inc)